Segmentation by Type (Factor V Leiden, Prothrombin 20210, Anti-Phospholipid Syndrome, and Others); by Drugs (Heparin, Warfarin, and Others); and by End User (Hospitals, Homecare, Specialty Centers, and Others) – Global Demand Analysis & Opportunity Outlook 2030
Buy Now
On the basis of geographical analysis, the global thrombophilia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing investments for improving healthcare infrastructure, and larger patient pool in the region. Moreover, the market in North America is expected to occupy the largest share during the forecast period ascribing to the rising demand for progressive treatment options, and early adoption of technologies, especially in the United States. In addition, increasing geriatric population, and growing collaboration of domestic and international companies for awareness campaigns are also predicted to boost the region’s market growth in the coming years. As per the data given by Rural Health Information Hub, there are more than 46 million adults aged 65 years or older living in the United States as of 2019. By 2050, this number is anticipated to reach almost 90 million.
Get more information on this report: Download Sample PDF
The global thrombophilia treatment market is further classified on the basis of region as follows:
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global thrombophilia treatment market includes the following segments:
By Type
By Drugs
By End User
Growth Drivers
Challenges
July 2021- Sanofi highlighted new research from first-in-class investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura.
September 2020- Aspen Global Incorporated announced that it has divested its wholly owned subsidiary incorporated in Mauritius with Mylan Ireland Limited. The latter will acquire all the intellectual property related to Aspen’s Thrombosis Business in Europe1.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: The major factors driving market growth are growing burden of obesity, and increasing prevalence of cardiovascular and trauma cases worldwide.
Ans: The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030.
Ans: Poor reimbursement policies provided by government is estimated to hamper the market growth.
Ans: Asia Pacific will provide more business opportunities for market growth owing to the growing investments for improving healthcare infrastructure, and larger patient pool in the region.
Ans: The major players in the market are Sanofi SA, Pfizer, Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, drugs, end user, and by region.
Ans: The hospitals segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
